Evaluating the Impact of Enteral Glutamine Supplementation on Preventing Ventilator-Associated Pneumonia: A Pilot Randomized Clinical Trial in Critically Ill Patients
Abstract
Background: Ventilator-associated pneumonia (VAP) is a common and serious complication of mechanical ventilation in intensive care units (ICUs). The current study evaluates the effectiveness of enteral glutamine (GLN) supplementation in preventing VAP in ICU patients.
Methods: This controlled, randomized clinical trial was performed on mechanically ventilated ICU patients who had a Clinical Pulmonary Infection Score (CPIS) of ≤ 6 within 48 hours of starting ventilation. Patients in the intervention group received 40 g of GLN during the first 48 hours after intubation, and this was continued for seven days. Both the intervention and control groups received standard preventive care. Outcomes were evaluated by comparing the incidence of VAP, the number of pneumonia-free days, and the duration of ventilation and ICU length of stay in each group.
Results: We analyzed the medical records of 613 patients to identify those who met the eligibility criteria for our study, resulting in a final cohort of 35 participants (16 in the intervention group and 19 in the control group). The present clinical trial did not reach its target sample size of 23 patients per group, primarily because of participant attrition and loss to follow-up. Our findings revealed no significant differences in the incidence of early, late, or overall VAP between the two groups. However, the number of pneumonia-free days was significantly higher in the intervention group compared to the control group (log-rank…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 613 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.